Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Levodopa

Criteria

Inclusion Criteria:

• Patients who have completed a previous AFQ056A study or are eligible as defined in the core study protocol

• Outpatients

• Patients who have a primary caregiver willing and able to assess the condition of the patient throughout the study in accordance with protocol requirements

Exclusion Criteria:

• Atypical or secondary form of Parkinson's disease

• History of surgical treatment for PD including deep brain stimulation

• Advanced, severe, or unstable disease (other than PD)

• History of malignancy

• Evidence of dementia

• Untreated/ineffectively treated mental disorders

• Treatment with certain prohibited medications

• Abnormal lab values or heart abnormalities

• Pregnant or nursing women